XFOR
X4 Pharmaceuticals·NASDAQ
--
--(--)
Market Open: --
--
--(--)
Pre-Market: --
XFOR fundamentals
X4 Pharmaceuticals (XFOR) released its earnings on Aug 8, 2025: revenue was 1.97M (YoY +250.44%), beat estimates; EPS was -3.47 (YoY -871.11%), beat estimates.
Revenue / YoY
1.97M
+250.44%
EPS / YoY
-3.47
-871.11%
Report date
Aug 8, 2025
EPS
Revenue
Revenue & Expenses
XFOR has released its 2025 Q3 earnings report, with revenue of 1.76M, reflecting a YoY change of 215.18%, and net profit of -29.82M, showing a YoY change of 18.75%. The Sankey diagram below clearly presents XFOR's revenue sources and cost distribution.
Key Indicators
X4 Pharmaceuticals (XFOR) key financial stats and ratios, covering profitability, financial health, and leverage.
X4 Pharmaceuticals (XFOR)'s revenue and profit trends over recent years, visualized with a waterfall chart to showcase the revenue-to-profit funnel.
Trend
Breakdown
X4 Pharmaceuticals (XFOR)'s asset and liability trends over recent years, visualized with a waterfall chart to illustrate changes in its asset-liability structure.
Trend
Breakdown
X4 Pharmaceuticals (XFOR)'s cash flow trends over recent years, visualized with a waterfall chart to illustrate changes in its operating, investing, and financing cash flows.
Trend
Breakdown
Where does X4 Pharmaceuticals (XFOR) generate its revenue? Explore its key revenue streams and top earning regions.
By Business
Data source:
By Region
Data source:
Track X4 Pharmaceuticals (XFOR) Dividend Yield, Payout Ratio & Sustainability Through Its Dividend History
Payout Ratio
Dividend Yield
You can ask Aime
What factors drove the changes in X4 Pharmaceuticals's revenue and profit?What is X4 Pharmaceuticals's gross profit margin?What does X4 Pharmaceuticals do and what are its main business segments?What is the market's earnings forecast for X4 Pharmaceuticals next quarter?What is the revenue and EPS growth rate for X4 Pharmaceuticals year over year?What is X4 Pharmaceuticals's latest dividend and current dividend yield?Did X4 Pharmaceuticals beat or miss consensus estimates last quarter?What were the key takeaways from X4 Pharmaceuticals’s earnings call?
